CAL-101,a novel agent of targeted therapy in hematological malignancies.
10.7534/j.issn.1009-2137.2014.02.049
- Author:
Chan-Juan LI
1
;
Qing ZHANG
1
;
Yi-Zhuo ZHANG
2
Author Information
1. Department of Hematology, Tianjin Medical University Cancer Institue and Hospial, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Thearpy, Tianjin 300060, China.
2. Department of Hematology, Tianjin Medical University Cancer Institue and Hospial, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Thearpy, Tianjin 300060, China. E-mail: yizhuozhang@163.com.
- Publication Type:Journal Article
- MeSH:
Animals;
Class Ia Phosphatidylinositol 3-Kinase;
antagonists & inhibitors;
Hematologic Neoplasms;
drug therapy;
Humans;
Purines;
pharmacology;
therapeutic use;
Quinazolinones;
pharmacology;
therapeutic use;
Signal Transduction;
drug effects
- From:
Journal of Experimental Hematology
2014;22(2):530-533
- CountryChina
- Language:Chinese
-
Abstract:
CAL-101 is a selective inhibitor of the phosphatidylinositol-3 kinase (PI3K), it inhibits the survival, proliferation and migration of tumor cells by directly inducing apoptosis and inhibiting micro-environmental interactions. It has been determined that the P110δ isoforms of PI3K expressed primarily in cells of hematopoietic lineage, such as B and T cells. This review focuses on the target, mechanism of action, the use and prospect of CAL-101 in tumors of blood and lymph systems.
